Monitor the Q3 2026 earnings call on October 29 for any guidance updates and the timing of a permanent CFO appointment. The orderly transition and reaffirmed guidance suggest limited near-term disruption, but a prolonged CFO search could weigh on sentiment.
Price Chart
Executive Summary
Insmed announced CFO Sara Bonstein will step down on October 30, 2026, with a search underway for a successor. The company reaffirmed full-year 2026 revenue guidance of $1.25B-$1.40B for BRINSUPRI and $450M-$470M for ARIKAYCE. The CFO departure is orderly and not related to any accounting or operational disagreements, but introduces leadership uncertainty during a key commercial phase.
Key Facts
- CFO Sara Bonstein to step down effective October 30, 2026, after nearly seven years
- Transition is not related to any disagreement on accounting, financial statements, internal controls, or operations
- Company reaffirms full-year 2026 guidance: BRINSUPRI revenue $1.25B-$1.40B, ARIKAYCE revenue $450M-$470M
- CEO stated Insmed is 'well positioned to reach cash flow positivity next year'
- CFO will participate in Q3 2026 earnings call on October 29, 2026
- Executive search firm engaged to identify next CFO
Financial Impact
Full-year 2026 revenue reaffirmed at $1.25B-$1.40B for BRINSUPRI and $450M-$470M for ARIKAYCE; no financial figures from prior periods provided for comparison
Risk Factors
- Extended CFO search period may create operational uncertainty
- Potential for interim CFO to lack strategic depth during critical commercial ramp
- Any future guidance revision would be more impactful without a permanent CFO in place
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-038529 |
| Document: ef20083216_8k.htm | 0001140361-26-038529 |
| Document: 0001140361-26-038529-index-headers.html | 0001140361-26-038529 |
| Document: 0001140361-26-038529-index.html | 0001140361-26-038529 |
| Document: 0001140361-26-038529.txt | 0001140361-26-038529 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | Institutional Cluster | $94.04 | awaiting T+20 | — | $94.96 (+0.98%) |
Oct 20, 2026 7d ago | 8-K | $95.67 | awaiting T+20 | — | $94.96 (−0.74%) |
Oct 5, 2026 22d ago | 8-K | $103.83 | awaiting T+20 | — | $94.96 (−8.54%) |
Aug 19, 2026 9w ago | Insider Cluster | $125.08 $120.00 | ▼ −4.06% | ▼ −4.19% | $94.96 (−24.08%) |
Aug 12, 2026 10w ago | Insider Cluster | $126.33 $129.41 | ▲ +2.44% | ▲ +4.19% | $94.96 (−24.83%) |
Aug 6, 2026 11w ago | 8-K | $132.55 $126.68 | ▼ −4.43% | ▼ −5.03% | $94.96 (−28.36%) |
Jul 24, 2026 13w ago | Institutional Cluster | $106.92 $125.77 | ▲ +17.63% | ▲ +14.00% | $94.96 (−11.19%) |
Jul 21, 2026 14w ago | ANALYST-UPGRADE | $108.62 $128.46 | ▲ +18.27% | ▲ +15.70% | $94.96 (−12.58%) |
Jul 16, 2026 14w ago | 8-K | $107.46 $126.33 | ▲ +17.56% | ▲ +13.94% | $94.96 (−11.63%) |
Jun 26, 2026 17w ago | Insider Cluster | $104.74 $106.92 | ▲ +2.08% | ▲ +2.36% | $94.96 (−9.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers